The drug was prescribed to promote muscle regrowth in disorders which cause involuntary weight loss, and is used as part of treatment for HIV/AIDS . It had also been shown to be partially successful in treating cases of osteoporosis . However, in part due to bad publicity from its illicit use by bodybuilders , production of Anavar was discontinued by Searle Laboratories in 1989. It was picked up by Bio-Technology General Corporation, which changed its name to Savient Pharmaceuticals , which following successful clinical trials in 1995, released it under the tradename Oxandrin.  BTG subsequently won approvals for orphan drug status by the Food and Drug Administration for treating alcoholic hepatitis , Turner syndrome , and HIV-induced weight loss . It is also indicated as an offset to protein catabolism caused by long-term administration of corticosteroids .